Screener
PBE vs GNOM
Invesco Biotechnology & Genome ETF vs Global X Genomics & Biotechnology ETF
Key differences
- GNOM costs 0.08% less per year.
- PBE is significantly larger than GNOM — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, PBE has delivered higher annualized returns.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| PBE | GNOM | |
|---|---|---|
| Annual cost (TER) | 0.58% | 0.50% |
| Fund size (AUM) | $247M | $51M |
| Since | 2005 | 2019 |
| Dividend yield | 1.09% | 1.38% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +34.1% | +53.6% |
| CAGR 3Y | +10.3% | -2.6% |
| CAGR 5Y | +3.3% | -10.5% |
| Sharpe 3Y | 0.41 | -0.06 |
| Volatility 1Y | 18.63% | 26.15% |
| Max drawdown | -37.84% | -75.00% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PBE and GNOM
Explore further